Ayandia Takes a Hit but Survives

摘要

Following two days ofrncontentious discussion, a federal advisory committee recommended keeping the troubled diabetes drug Avandia (rosiglitazone) on the market, but with added restrictions. The panel was deeply divided, with 12 members voting to ban the drug and 17 advocating its continued sale with stricter warnings and limited use for certain patients.